How did ANIX's Q2 2023 earnings surprise investors?

**Anixa Biosciences' Q2 2023 earnings did not provide a positive surprise to investors**. Here are the details:

1. **Financial Performance**: The company reported sales of USD 0.21 million for the second quarter ended April 30, 2023. This indicates a relatively low revenue stream, which might have contributed to the lack of earnings surprise.
2. **Net Loss**: Anixa Biosciences reported a net loss of USD 2.29 million for the quarter. While this is an improvement from the USD 3.54 million net loss reported in the same quarter a year ago, it did not result in a positive surprise, as investors might have anticipated a larger reduction in losses.
3. **Earnings Per Share (EPS)**: The company did not provide information on the Actual EPS for Q2 2023. However, given the context of the net loss, it can be inferred that the EPS was negative, but the magnitude is not detailed.
4. **Analyst Expectations**: It is difficult to gauge analyst expectations without specific data. However, the average price target of $10.6 from five bullish analysts suggests a potential upside from the current price. If the earnings fell short of even these expectations, it could have disappointed investors.

In summary, while Anixa Biosciences showed improvement in its financials compared to the previous year, the actual figures did not exceed investor expectations, as indicated by the lack of earnings surprise.